odprn logo ODPRN

Resources for Policymakers

Opioids

Resource Type Year Download
High-Dose Opioid Prescribing and Opioid-Related Hospitalization Research Minute 2016 pdf
High-Dose Opioid Prescribing and Opioid-Related Hospitalization Infographic 2016 png
Opioid Use and Related Adverse Events in Ontario Interactive 2016 web page
High Strength Opioid Formulations in Ontario: By the Numbers Research Summary 2016 pdf
Off-label use of inhaled tobramycin in Ontario Canada Research Minute 2016 pdf
Evaluating the effectiveness of first-time methadone maintenance therapy across northern rural and urban regions of Ontario Research Minute 2015 pdf
Sex differences in dose escalation and overdose death during chronic opioid therapy Research Minute 2015 pdf
Opioid-related mortality Research Minute 2014 pdf
Neonatal opioid withdrawal and antenatal opioid prescribing Research Minute 2015 pdf
Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario Research Minute 2014 pdf
High dose prescribing of opioids in Canada Research Minute 2014 pdf
The effects of a course-based intervention on physician prescribing of opioids Research Minute 2013 pdf
Opioids and road trauma Research Minute 2013 pdf
Opioids prescribing and use at U.S.- Canada border crossings Research Minute 2012 pdf
Geographical variations in opioids prescribing across Ontario Research Minute 2012 pdf
Opioid dose and drug-related mortality Research Minute 2011 pdf

Diabetes

Resource Type Year Download
Association of a Blood Glucose Test Strip Quantity-Limit Policy With Patient Outcomes Research Minute 2016 pdf
Self-monitoring of blood glucose levels:  evaluating the impact of a policy of quantity limits on test-strip use and costs Research Minute 2016 pdf
The impact of blood glucose test strip utilization and costs in Canada Research Minute  2015 pdf
Blood glucose test strips: Options to reduce usage Research Minute 2009 pdf

Adverse events

Resource Type Year Download
Safety of Proton-Pump Inhibitors and Clopidogrel Research Minute 2009 pdf
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone Research Minute 2014 pdf

Adherence to prescribing standards

Resource Type Year Download
Professional pharmacy services and patient complexity: an observational study Research Minute 2015 pdf
Adherence to prescribing recommendations made on a provincial formulary Research Minute 2014 pdf

Allergen Immunotherapy

Resource Type Year Download
Allergen immunotherapy: Drug Class Review Findings Research Summary 2015 pdf
Allergen immunotherapy: Drug Class Review Findings Infographic 2015 pdf

Chronic Hepatitis B

Resource Type Year Download
Chronic hepatitis B: Drug Class Review Findings Research Summary 2015 pdf
Chronic hepatitis B: Drug Class Review Findings Infographic 2015 pdf

Cognitive Enhancers

Resource Type Year Download
Cognitive Enhancers for the treatment of Alzheimer's disease: Drug Class Review Findings Research Summary 2015 pdf

Antipsychotics in the Elderly

Resource Type Year Download
Antipsychotics in the Elderly: Drug Class Review Findings Drug Class Review Summary 2015 pdf

Respiratory Therapies

Resource Type Year Download
ICS+LABA combination products for asthma and COPD: Drug Class Review Findings Research Summary 2015 pdf
ICS+LABA combination products for asthma and COPD: Drug Class Review Findings Infographic 2015  pdf
LAMAs for COPD: Drug Class Review Findings Research Summary 2015 pdf
LAMAs for COPD: Drug Class Review Findings Infographic 2015 pdf

Testosterone Replacement Therapy

Resource Type Year Download
The impact of drug reimbursement policy on rates of testosterone replacement therapy among older men Research Minute 2014 pdf
Testosterone Replacement Therapy: Drug Class Review Findings Drug Class Review Summary 2014 pdf

Triptans

Resource Type Year Download
Triptans for Migraine Therapy: Drug Class Review Findings Drug Class Review Summary 2014 pdf

 

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.